{"id":"adt-for-2-years","safety":{"commonSideEffects":[{"rate":"80-90%","effect":"Hot flashes"},{"rate":"50-70%","effect":"Erectile dysfunction"},{"rate":"30-50%","effect":"Fatigue"},{"rate":"20-40%","effect":"Osteoporosis"},{"rate":"10-30%","effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL521875","moleculeType":"Small molecule","molecularWeight":"460.53"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"ADT works by targeting the androgen receptors in cancer cells, thereby inhibiting their growth and proliferation. This can be achieved through the use of medications that block the production of androgens or interfere with their action on cancer cells.","oneSentence":"Androgen deprivation therapy (ADT) involves the use of medications to suppress the production of androgens, such as testosterone, which can fuel the growth of certain types of cancer.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:19:41.505Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prostate cancer"},{"name":"Metastatic prostate cancer"}]},"trialDetails":[{"nctId":"NCT04191096","phase":"PHASE3","title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-12","conditions":"Metastatic Hormone-Sensitive Prostate Cancer","enrollment":1251},{"nctId":"NCT07477626","phase":"PHASE3","title":"Radiotherapy After Prostatectomy for Node Positive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-01-06","conditions":"Prostate Cancer (Post Prostatectomy), Radiotherapy; Image-Guided, Prostate Cancer Non-Metastatic","enrollment":374},{"nctId":"NCT05884398","phase":"PHASE3","title":"A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2023-08-31","conditions":"Metastatic Castrate-sensitive Prostate Cancer","enrollment":420},{"nctId":"NCT01546987","phase":"PHASE3","title":"Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2012-05","conditions":"Prostate Cancer","enrollment":239},{"nctId":"NCT07444983","phase":"NA","title":"Rezvilutamide for High-Risk Prostate Cancer After Surgery","status":"NOT_YET_RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2026-02-11","conditions":"Prostate Cancer (Adenocarcinoma)","enrollment":33},{"nctId":"NCT06111313","phase":"PHASE2","title":"The University of Miami Adapt (UAdapt) Trial","status":"RECRUITING","sponsor":"University of Miami","startDate":"2024-11-06","conditions":"Prostate Cancer","enrollment":130},{"nctId":"NCT03543189","phase":"PHASE1, PHASE2","title":"Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-10-03","conditions":"Prostate Cancer, Prostate Disease","enrollment":44},{"nctId":"NCT03456843","phase":"PHASE2","title":"Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","startDate":"2018-03-20","conditions":"Stage IV Prostate Adenocarcinoma AJCC v7","enrollment":190},{"nctId":"NCT07302451","phase":"PHASE2","title":"REDI-CaP(Recovery of Erectile Dysfunction Induced in Prostate Cancer Patients)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute, Naples","startDate":"2025-12-01","conditions":"Prostate Cancer (Adenocarcinoma)","enrollment":50},{"nctId":"NCT05628363","phase":"NA","title":"Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2023-01-18","conditions":"Prostate Cancer, Cancer of the Prostate","enrollment":28},{"nctId":"NCT06392841","phase":"PHASE2","title":"Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations","status":"WITHDRAWN","sponsor":"Qian Qin","startDate":"2025-10","conditions":"Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Deleterious HRR Gene Mutation, BRCA1 Gene Mutation","enrollment":""},{"nctId":"NCT04934722","phase":"PHASE3","title":"Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-05-25","conditions":"Metastatic Hormone-Sensitive Prostate Cancer","enrollment":186},{"nctId":"NCT06348264","phase":"PHASE2","title":"Adjuvant Rezvilutamide in Combination With Androgen Deprivation Therapy in Androgen Receptor-positive, High-risk Salivary Duct Carcinoma","status":"RECRUITING","sponsor":"Peking University First Hospital","startDate":"2024-10-10","conditions":"Salivary Gland Neoplasm Duct","enrollment":37},{"nctId":"NCT04775355","phase":"","title":"Study to Detect Changes in Urinary and Gut Microbiome During Androgen Deprivation Therapy and Radiation Therapy in Patients With Prostate Cancer","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2021-04-14","conditions":"Stage I Prostate Cancer AJCC v7, Stage II Prostate Cancer AJCC v7, Stage IIA Prostate Cancer AJCC v7","enrollment":30},{"nctId":"NCT06687421","phase":"","title":"Implementation of Precision Medicine in High-risk Prostate Cancer","status":"RECRUITING","sponsor":"Andreas Josefsson","startDate":"2024-06-10","conditions":"Prostate Cancer","enrollment":5500},{"nctId":"NCT01952223","phase":"PHASE3","title":"A Phase III of Cabazitaxel and Pelvic Radiotherapy in Localized Prostate Cancer and High-risk Features of Relapse","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2013-12","conditions":"Adenocarcinoma of Prostate, Progression of Prostate Cancer","enrollment":761},{"nctId":"NCT05448547","phase":"PHASE3","title":"Immediate Curative vs Conservative Treatment in Older Men With M0, High-risk Prostate Cancer","status":"RECRUITING","sponsor":"Sven Löffeler","startDate":"2022-11-04","conditions":"Prostate Cancer","enrollment":980},{"nctId":"NCT06625970","phase":"PHASE3","title":"Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2025-04-10","conditions":"High Risk Prostate Carcinoma, Prostate Cancer","enrollment":700},{"nctId":"NCT06992232","phase":"PHASE2","title":"Radiotherapy or Surgery Combined With Intense Androgen Deprivation Therapy for mCRPC","status":"RECRUITING","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2024-08-01","conditions":"Prostate Cancer Metastatic Disease","enrollment":144},{"nctId":"NCT06818682","phase":"PHASE2","title":"Reduced Length of ADT and ARTA With XRT in High-Risk Prostate Cancer (RELAX): A Randomised Trial","status":"RECRUITING","sponsor":"Tata Memorial Centre","startDate":"2025-02-17","conditions":"Prostate Carcinoma","enrollment":206},{"nctId":"NCT06276465","phase":"PHASE3","title":"Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2024-10-07","conditions":"Prostatic Cancer, Castration-Resistant","enrollment":336},{"nctId":"NCT06500247","phase":"PHASE2","title":"Darxicilib Combined With Abiraterone Acetate Tablets (II) for the Treatment of Advanced Metastatic Castration-resistant Prostate Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2024-07-31","conditions":"The Efficacy of Abiraterone Acetate Combined With Dalpicilib in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer","enrollment":43},{"nctId":"NCT03311555","phase":"PHASE2","title":"A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)","status":"COMPLETED","sponsor":"Andrew J. Armstrong, MD","startDate":"2018-03-28","conditions":"Prostate Cancer","enrollment":39},{"nctId":"NCT06198387","phase":"NA","title":"Radiotherapy for Prostate and Oligo-metastatic Lesions in Patients With Low-burden Oligo-metastatic Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Changhai Hospital","startDate":"2024-01-01","conditions":"Oligo-metastatic Prostate Carcinoma","enrollment":30},{"nctId":"NCT03241537","phase":"PHASE3","title":"COHORT Trial in Clinical Pelivc Lymph Node Metastatic Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Samsung Medical Center","startDate":"2016-01-15","conditions":"Prostate Neoplasm","enrollment":61},{"nctId":"NCT03996993","phase":"","title":"Defining Recurrent Disease With Axumin™","status":"UNKNOWN","sponsor":"Cancer Center of Irvine","startDate":"2019-07-01","conditions":"Prostate Cancer, Prostate Adenocarcinoma","enrollment":20},{"nctId":"NCT01696877","phase":"PHASE1, PHASE2","title":"A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2013-01-18","conditions":"Prostate Cancer Adenocarcinoma in Situ","enrollment":29},{"nctId":"NCT00470834","phase":"PHASE4","title":"Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation Therapy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-05","conditions":"Neoplasms, Prostate","enrollment":127},{"nctId":"NCT00521781","phase":"PHASE2","title":"Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer","status":"TERMINATED","sponsor":"The Methodist Hospital Research Institute","startDate":"2007-08","conditions":"Prostatic Neoplasms","enrollment":14},{"nctId":"NCT00743327","phase":"","title":"Androgen Deprivation Therapy Study","status":"TERMINATED","sponsor":"National Institute on Aging (NIA)","startDate":"2008-10","conditions":"Hypogonadism, Metabolic Syndrome, Diabetes","enrollment":1}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":31,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ADT for 2 years","genericName":"ADT for 2 years","companyName":"Tata Memorial Centre","companyId":"tata-memorial-centre","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Androgen deprivation therapy (ADT) involves the use of medications to suppress the production of androgens, such as testosterone, which can fuel the growth of certain types of cancer. Used for Prostate cancer, Metastatic prostate cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}